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Summary 
Dendritic  cells (DC)  are the most efficient APC for T  cells. The clinical use of DC as vectors 
for anti-tumor and infectious disease immunotherapy has been limited by their trace levels and 
accessibility in normal tissue and terminal state of differentiation.  In the present study, daily in- 
jection of human  Flt3 ligand  (Flt3L) into mice results in a dramatic numerical increase in cells 
co-expressing the characteristic DC markers--class II MHC,  CD11c, DEC205,  and CD86.  In 
contrast,  in mice treated with either GM-CSF,  GM-CSF plus IL-4, c-kit ligand  (c-kltL), or 
G-CSF,  class II  ÷  CDllc ÷ cells were  not  significantly increased.  Five distinct  DC subpopula- 
tions were identified  in the spleen of Flt3L-treated  mice using CDSot and CD11b  expression. 
These  cells exhibited  veiled and dendritic  processes and were  as  efficient as  rare,  mature DC 
isolated from the spleens of untreated mice at presenting allo-Ag or soluble Ag to T  cells, or in 
priming an Ag-specific T  cell response in vivo. Dramatic numerical increases in DC were de- 
tected in the bone marrow, gastro-intestinal lymphoid tissue (GALT), liver, lymph nodes, lung, 
peripheral blood,  peritoneal  cavity, spleen,  and thymus.  These results suggest that Flt3L could 
be used to expand the numbers of functionally mature DC in vivo for use in clinical immuno- 
therapy. 
D 
endritic  cells  (DC) l  are  rare  bone  marrow-derived 
cells that are predominantly found in the T  cell-depen- 
dent areas of lymphoid tissue, as well as other tissues of the 
body (1).  These cells express high levels of class I and class 
II MHC  proteins,  CD11c  (2),  the  mannose  receptor-like 
protein  DEC205  (3,  4),  and  adhesion  and  costimulatory 
molecules  (1).  A  substantial proportion  of DC also express 
CD8o~ as a homodimer (5). DC specialize in processing and 
presenting  foreign  and  self Ag to  induce  immunity  (1)  or 
tolerance (6, 7). 
The lineage derivation of DC remains controversial, but 
there  is growing evidence  that DC  can be subdivided into 
myeloid-derived (8-17)  and lymphoid-derived populations 
(17-19).  The  myeloid  relationship  of DC  is based mainly 
upon in vitro experimentation.  In vitro, DC can be gener- 
ated from bone  marrow or cord blood progenitors  as well 
as PBMC using GM-CSF but not M-CSF or G-CSF (9-11). 
Other  growth  factors  that  can  enhance  the  GM-CSF- 
1Abbreviations used in  this paper: BM,  bone  marrow  cells; c-kitL,  c-kit 
hgand; DC, dendntxc cells; Flt3L, Flt3 hgand; MSA, mouse serum albu- 
min; PC, peripheral blood; PP, Peyer's patches 
dependent  in vitro generation  of DC are TNF-ot  (12-16), 
IL-4 (13, 14), and c-kitL (15, 16). These studies show that in 
the presence of GM-CSF,  DC can be generated  either di- 
rectly from a myeloid-committed precursor (that also gives rise 
to monocytes and granulocytes)  (11), or from a myelomono- 
cytic intermediate that gives rise to monocytes (15-17).  Al- 
ternatively,  PBMC  cultured  with  GM-CSF  and  IL-4 can 
transiently differentiate into DC-like cells (13,  14). DC can 
also arise from the most immature T  cell precursors or bone 
marrow  progenitors,  which  can  also  generate  NK  and  B 
cells but not cells of the myeloid lineage  (17-19).  Interest- 
ingly,  GM-CSF  does  not  appear to  be  necessary  for DC 
generation from lymphoid-committed precursors (19,  19a). 
In addition,  although  DC  can be generated  in vitro using 
GM-CSF,  tlie  increased  level  of GM-CSF  in  GM-CSF 
transgenic  mice  does  not  increase  the  number  of DC  in 
lymphoid  tissue  suggesting  that  other  growth  factors  are 
important for DC generation in vivo (20). 
By virtue  of their  highly  developed  Ag-presenting  ca- 
pacity, the use of DC as cellular vectors for anti-tumor and 
infectious  disease vaccines or as inducers  of transplantation 
tolerance  is a  promising immunotherapy  strategy  (21, 22, 
reviewed in reference 23).  However, the clinical feasibility 
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cause  only limited DC  numbers can be generated in vitro 
from  bone  marrow  progenitors  or  PBMC,  and  only one 
lineage  of DC  (myeloid-derived)  is  generated  due  to  the 
use of GM-CSF  (8,  9,  11-17,  21,  22).  While studying the 
growth factor requirements for DC  generation in vivo, we 
examined the  effects  of administering a  recently identified 
hematopoietic  growth  factor,  Flt3L  (24).  Flt3L  has  been 
shown to stimulate the proliferation ofhematopoietic stem 
and progenitor  cells  (reviewed  in reference  25,  26).  Fur- 
thermore,  in vivo administration of Flt3L has been shown 
to dramatically increase the numbers of hematopoietic pro- 
genitors in the bone marrow,  peripheral blood and spleen, 
resulting in  enhanced  myelopoiesis  and  B  lymphopoiesls 
(27,  28). We now report that the in vivo admimstration of 
Flt3L has  a  profound effect  upon  the  generation of func- 
tionally mature DC  in multiple organs in mice. Both lym- 
phoid-  and  myeloid-derived  DC  populations  have  been 
identified in the spleens of these mice. Furthermore, the in 
vivo  administration of either  GM-CSF,  or  GM-CSF  and 
IL-4, or c-kitL, or G-CSF did not significantly increase the 
numbers of spleen DC, suggesting a distinct effect of Flt3L 
on in vivo DC generation. 
Materials and Methods 
Mice and Cytokine Treatment  Protocols.  Female  C57B1/6  mice 
(4-8 wk of age) were obtained from the Jackson Laboratory (Bar 
Harbor, ME)  and kept in a specific pathogen-free facility. Mice 
(4-5 per group) were injected once daily (subcutaneously at the 
nape of the neck) with either mouse serum albumin (MSA)  (1  b~g) 
or with MSA plus human Chinese hamster ovary cell (CHO)- 
derived Flt3L (10 p~g) for nine consecutive days. Additional treat- 
ment groups included daily subcutaneous injections for 11 d with 
either MSA alone (1 tag) or with MSA plus Flt3L, or human G-CSF 
(Neupogen; Amgen, Thousand Oaks,  CA),  or mouse GM-CSF 
(10  p~g; Immunex, Seattle, WA), or c-kit ligand (10 I~g; Immn- 
nex), or combinations of Flt3L and G-CSF or GM-CSF (10 p,g 
each, respectively), or muGM-CSF and mulL-4 (10 lag each, re- 
spectively; Immunex). 
Cell Preparations and Flow Cytometric Isolation.  Flow  cytometnc 
analysis of various organs from  cytokme-treated mice  was  per- 
formed on a FACStar  ® Plus (Becton Dickinson, San Jose,  CA). 
Briefly,  single cell suspensaons from  liver,  inguinal and axillary 
LN,  Peyer's patches  (PP), spleen, and thymus were prepared by 
disrupting the  organs between frosted  glass slides  and depleting 
RBC with NHzC1.  PBMC were isolated after centrifugation of 
peripheral  blood  over  a  discontinuous  density  gradient  using 
Lympholyte M  (Cedalene, Ontario, Canada). Bone marrow cells 
(BM)  were  isolated by syringe extraction.  Cells from  the  lungs 
were  obtained by lung lavage using PBS.  Cells from the perito- 
neal cavity were obtained by peritoneal washings with PBS. Cells 
from the various organs were then incubated with directly conju- 
gated  antibodies  as  indicated  (PharMingen,  San  Diego,  CA; 
NLDC145  [anti-DEC205]  was  a  kind gift from  Dr.  G.  Kraal, 
Free University, Amsterdam, The Netherlands) for 30 mln at 4°C 
together with 50  b~g/ml of anta-FclLII'y mAb (2.4G2)  to block 
Fc-receptors,  and the  cells  were  then analyzed with propidium 
iodide (1  Ixg/ml) to exclude dead and dying cells.  Cytospins of 
sorted cells  were prepared by spinning (500 rpm)  5  ×  104 cells 
onto slides followed by staining with Wnght-Giemsa according to 
the manufacturers instructions (Fisher Diagnostics, Pittsburgh, PA). 
Isolation of DC from Flt3L-treated  and Control Mice.  Single  cell 
suspensions of spleens were prepared from mace treated for either 
9 or 11 d with Flt3L. Spleen cells were depleted of RBC and in- 
cubated with mAb to Thy-1, B220, NK1.1, and the erythroid Ag 
TER_119  for 30 mln at 4°C. The cells were incubated at 37°C for 
30 mm in serum-free RPMI-1640 medium containing 10% rab- 
bit complement (Pel  Freez Biologlcals, Rogers,  AK).  The  cells 
were then washed and residual mAb-coated cells were removed 
using anti-immunoglobulin (Ig)-coated  magnetic beads  (Dyna- 
beads; Dynal, Oslo, Norway). The ennched cells were incubated 
with antl-CD1 lc, anti-CD1 lb, and anti-CD81x. The vanous cell 
populations were  then sorted.  Control DC were  isolated as de- 
scribed (5). Briefly, C57B1/6 spleen fragments were digested with 
collagenase and DNase  for  25  min at  room  temperature,  then 
treated with EDTA for 5 min. Light density cells were selected by 
centrifugation in Metrizamide  medium  (Nyegaard  Diagnostics, 
Oslo, Norway;  1.068 g/cm  3, pH 7.2, 4°C). These cells were in- 
cubated with mAb against CD3, CD4, Thyl, IL-2R(x, B220, Gr-1, 
CD1 lb, F4/80 Ag, FcR.II, and TER119 followed by removal of 
non DC using anti-Ig-coated magnenc beads. The enriched cells 
(~70% DC) were stained with anti-class II and anti-CD11c and 
class II  + CD11c + DC were sorted. 
Preparation and Purification of Alloreactive and Ag-specific  CD4 + T 
Cells.  CD4 +  T  cells  (90-95%  pure)  were  isolated from  either 
the  LN  of 4-8-wk-old DBA/2  (H-2  a allogeneic) mice or from 
the inguinal draining LN of 8-wk-old C57BL/6 (H-2  b syngeneic) 
mice  7  d  after immunization with  keyhole limpet hemocyanin 
(KLH) (50 ~g; Pierce Chem. Co., Rockford, IL) in adjuvant (P,  abi 
Immunochem Inc.,  Hamilton, MT;  MPL  TM  +  TDM  +  CWS 
emulsion). Lymph node  cells  were  incubated with  anti-CD80:, 
anti-class II  (H-2  b or H-2  d)  and anti-B220, and Ab-coated cells 
depleted with anti-Ig-coated magnetic beads. Depleted LN cells 
were  composed of at least 95% CD4 + T  cells  as determined by 
FACS  ® analysis. 
Mixed Lymphocyte Reaction  (MLR)  and  KLH-specific Presentation 
Assays.  The ML1L and KLH presentation assays were performed 
in 96-well round-bottom culture plates. Allogenelc or KLH-spe- 
cific CD4 + T  cells  (1  ×  l0  s) were incubated with varying num- 
bers of the indicated sorted spleen cell populations from Flt3L- 
treated mice or control DC in 0.2 ml modified DMEM medium 
containing 10% FCS and 10 -4 M  2-ME (culture medium) m hu- 
midified 10% CO2-m-alr for 5 d.  The cultures were pulsed with 
0.5 ~C1 [3H]thymidine for 5 h and the cells were harvested onto 
glass  fiber sheets  for  counting on  a  gas-phase  [3  counter.  The 
background counts for  either T  cells  or DC  cultured alone or 
KLH-specific T  cells cultured with KLH were <  100 cpm, <100 
cpm, and <800 cpm, respectively. 
Priming of T  Cells hi  Vivo with Ag Pulsed DC.  To detect in vivo 
Ag presenting capacity, class II  + CD11c + spleen cells from Flt3L- 
treated mice (Flt3L DC) and control DC were cultured for 18 h 
an  culture  medium w~th  or without  5  btg/ml  KLH.  The  cells 
were then washed three times and 1 ×  10  s cells were ln3ected (m 
a volume of 0.02 ml PBS) into the foot pads of mice. Cells cul- 
tured an medium alone (-KLH) were injected into the contralat- 
eral foot pads as negative controls. Saline-only injected mice were 
also included as controls. After 7 d, the pophteal LN draining the 
foot pads were harvested, disrupted into a single cell suspensmn, 
and the  LN  cells  were  incubated with antl-CD8o~, ann-class II 
(IA  b) and anti-B220, and the Ab-coated cells were then depleted 
with Ig-coated magnetic beads. CD4 + T  cells were incubated (1 × 
l0  s  T  cells)  with  freshly isolated  control DC  (1  ×  104) in the 
1954  Flt3L Generates DC In Vlvo presence or absence of KLH (20 I~g/ml) in 0.2 ml cultures for 5 d. 
The cultures were pulsed with 0.5 I.tCi [3H]thymidine for 5 h. 
Results 
Flt3L Treatment of Mice Resulted in a Significant Increase of 
Cells Co-expressing Class II MHC,  CD11c,  DEC205,  and 
CD8a in Multiple Organs.  DC  are very rare in dissociated 
spleen cell suspensions. The majority of DC  require enzy- 
matic  digestion  for  release  from  the  splenic  stroma,  but 
even then they are an infrequent component of the suspen- 
sion  (29).  However, we found that unlike spleen cell sus- 
pensions  from  MSA-treated  control  mice,  mice  treated 
daily for 9  d  with subcutaneous injections of human  Flt3L 
(derived from  CHO  cells)  resulted in  20%  of spleen  cells 
co-expressing class II MHC  and  the  DC  markers  CD11c 
and DEC205,  and 15% of spleen cells co-expressing class II 
MHC  and  CD8c~  (Fig.  1 A).  Further phenotypic analysis 
revealed that  MHC  class  II  +  CD11c +  cells were  CD3-, 
B220-,  Gr-l-,  NKI.1  ,  Ter119  ,  CDS0-,  but  CD86 + 
(Fig.  1 /3).  These cells could be separated into three pop- 
ulations  on  the  basis  of  CDllb  expression  (CD11b-, 
CD 11b  au" and  CDllb bnght) (Fig.  1  B).  Flt3L-treated mice 
show a 2-3-fold increase in spleen and lymph node cellu- 
larity  (26,  27).  The  absolute  number  of MHC  class  II  + 
CD1 lc + cells was increased by 17-fold in the spleen, 4-fold 
in the LN and 6-fold in the peripheral blood (PB) by day 9 
(Fig.  1  C).  MHC  class II  +  CDllc +  cells were  detected as 
early as  day  5  in the  spleen and  by day 7  in  LN  and  PB 
(Fig. 1 C). 
Five  Distinct  Populations of DC  Can  Be  Identified in  the 
Spleens of Flt3L-treated Mice.  To  further  define  the  cells ex- 
pressing markers characteristic of DC,  spleens from Flt3L- 
treated mice were depleted ofT  cells, B  cells, NK cells and 
cells of the erythroid lineage by incubating the spleen cells 
with  mAb  directed  against  Thyl.2,  B220,  NKI.1,  and 
Ter119,  followed by  depletion  of mAb-coated cells with 
rabbit  complement  and  two  rounds  of immunomagnetic 
bead  depletion.  Lymphocyte-depleted  spleen  cells  from 
Flt3L-treated mice were then examined for the expression 
of CD 11b and CD 1 lc (Fig. 2 A). Five distinct populations 
were identified. As shown in Fig. 2  B, the majority of cells 
within  population  A  (CDllbbng  ht  CDllc-)  were  MHC 
class  II-and  granulocyte  marker  Gr-1 +.  Population  B 
(CD 1 l b 6~ght CD 11c a~ll) was heterogeneous for both class II 
and  Gr-1.  The  majority  of  cells  within  population  C 
(CDllb br'ght CDllc +)  were  MHC  class lI  bnght and  Gr-1 
(with 20%  of ceils expressing low levels of Gr-1).  Unlike 
populations A  or B,  cells within populations D  (CD11b a~ll 
CD11c +)  and E  (CDllb  CD11c+),  as well as DC freshly 
isolated from  the  spleens  of untreated  mice  (control DC) 
were  MHC  class II  b~ght and  Gr-1-.  Furthermore, popula- 
tions A, B,  and  C  were  composed exclusively of CD8ci- 
ceils, whereas populations D  and E  as well as control DC 
could be  separated into  CD8ol-  and  CD8ot +  populations 
(Fig. 2  B). 
Wright-Giemsa staining of cytospins indicated that  cells 
within  population  A  were  highly  enriched  for  immature 
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Figure 1.  Flow cytomemc  analysis of spleen cells from mace treated 
with rather MSA or MSA plus Flt3L. (A) The distribution  of class II MHC 
and rather CD80t, CD11c, DEC205, on spleen cells C57BL/6 mice (five 
per group) were injected once dally, subcutaneously, wlth either MSA 
(1  btg) or with MSA plus human Flt3L derived from CHO (10 ptg) for 
nine consecutive days (B) The dlstnbutlon of B220, CD3, Gr-1, NKI.1, 
Ter119, CDllb, CD80, and CD86 on class II  + CDllc  + spleen cells. (C) 
The kmencs of generation of class II  + CD1 lc + cells m spleen, LN and 
peripheral blood from mice treated dally for 9 d with either MSA (open 
arcles) or with MSA plus Flt3L (closed arcles). Flow cytometnc analysis  of 
spleen cells, LN (inguinal, axlllary),  and PB was performed on a FACStar  ® 
Plus. Values represent the mean -+ SD of five trace. 
granulocytes or myeloid cells (Fig. 2  C). This is consistent 
with the expression of high levels of Gr-1  and CD11b and 
the lower levels of class II MHC.  Population B  was com- 
posed largely of immature myeloblasts. The blast-like mor- 
phology and heterogeneous levels of class II MHC  and Gr-1 
suggest that population B  represents a population undergo- 
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Figure 2,  Detection and function of multiple spleen cell popu/atlons in rmce after 11 d of treatment with Flt3L. (A) The distribution of CDt lc and 
CDllb on depleted spleen cells from Flt3L-treated mice showing the gates used for analysts of class II MHC, Gr-1 and CD80t expression (shown in  /3) 
and for cell sorting. (C) Idenuficatlon of spleen cell populations m Flt3L-treated mice with dendritic morphology. Cytospms were prepared for the vari- 
ous cell populations by spinning 5 X 104 cells onto slides (500 rpm) followed by staining with Wnght-Glemsa. 
ing differentiation,  Population  C  consisted of a mixture  of 
immature myeloblasts (similar to those found within popu- 
lation B) and more mature myeloid cells with dendritic and 
veiled processes.  Populations D  and E  that were either low 
or negative for CD1 l b  and bright for CD1 lc were highly 
enriched  for  cells  with  veiled  and  dendritic  processes  that 
were indistinguishable from control DC  (Fig. 2  C). 
Spleen  DC  from  Ht3L-treated  Mice  Are  Functional  APC. 
The  various  spleen  populations  from  Flt3L-treated  mice 
were  examined for their in vitro  capacity  to  stimulate  the 
proliferation  of allo-reactive  T  cells  in  an  MLR.  Spleen 
cells from Flt3L-treated mice were depleted of mature lym- 
phocytes,  and populations A, B,  C,  D, and E  were isolated 
by flow cytometry on the basis  of CDllc  and CD11b  ex- 
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Figure  3.  Comparison of the 
capacity  of the various spleen cell 
populanom in Ht3L-treated  mace 
to  mmulate  the  prohferation of 
allogenmc  or  KLH-speclfic 
CD4  +  T  cells  Populatmns  A 
(closed  circles),  B  (open  circles),  C 
(closed  triangles),  D  (open  triangles), 
and E  (closed  squares)  were com- 
pared  with  control  DC  (open 
squares)  isolated  from the spleens 
of untreated  mice.  Background 
control cultures (closed  star)  con- 
tamed  either  DBA/2  allogenelc 
T  cells alone or C57B1/6 synge- 
nelc  KLH-speclfiC  T  cells  plus 
KLH  alone.  The  background 
counts were  <100  cpm or  800 
cpm, respectively. 
pression. When the various spleen populations from Flt3L- 
treated  mice were compared with the  rare freshly isolated 
control DC in an MLR, it was found that cells from popu- 
lations C, D, and E were as efficient as control DC at stim- 
ulating the proliferation ofallogeneic DBA/2-derived T  cells 
(Fig. 3, upper  panels). In contrast, cells from populations A  and 
B were 30-fold less efficient as APC compared with control 
DC  (Fig.  3,  upper panels).  Similarly,  cells  from populations 
C, D, and E, but not populations A and B, were as efficient 
as control DC at stimulating the proliferation of syngeneic 
KLH-specific  T  cells  in  a  KLH presentation  assay  (Fig.  3, 
lower panels). This indicates that populations C, D, and E  are 
not only composed of cells that appear morphologically like 
DC and express ceil surface Ag characteristic of DC, but are 
also as  efficient as  control DC  at  stimulating  alloreactive  T 
ceils and processing and presenting soluble Ag to Ag-specific 
T  cells.  Since populations D  and E, which are either dull or 
negative for CD1 lb expression,  can be further separated us- 
ing CDSot expression, a total of five DC subpopulations can 
be detected in the spleens of Flt3L-treated mice. 
Ag-pulsed  Spleen DC  from Ht3L-treated Mice Are E~cient at 
Priming an Ag-specific Immune Response In Vivo.  DC  have 
been previously shown to initiate  an Ag-speclfiC immune 
response when pulsed with soluble Ag ex vwo and then in- 
jected into  mice  (30).  We  compared the  capacity of class 
II  + CDllc + spleen DC generated from Flt3L-treated mice 
(Flt3L DC)  with control DC to generate  a T  cell~specific 
immune response in vivo after exposure to soluble KLH ex 
vivo.  Both  Flt3L-DC  and  control  DC  were  cultured  in 
vitro  with  or without  soluble  KLH for  18  h.  These  cells 
were then washed and  1 ×  10  s KLH-pulsed DC were in- 
jected  into  the  foot pads  of naive  mice.  DC  cultured  in 
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medium alone were injected into the contralateral footpads 
as  Ag-specificity  controls.  After  7  d,  the  popliteal  LN 
draining  the  footpads  were  harvested  and  CD4 +  T  cells 
were purified  and restimulated  in vitro with  soluble  KLH 
presented  by  freshly  isolated  control  DC.  KLH-pulsed 
Flt3L-DC were as  efficient as KLH-pulsed control DC  at 
generating KLH-specific T  ceils in the draining LN of mice 
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Figure  4.  The mducnon ofKLH-speclfic T  cells in the draining LN  of 
mice rejected with KLH-pulsed DC. Class lI ÷ CDllc ÷ spleen cells from 
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(Fig.  4).  KLH-specific  T  cells were  not  significantly de- 
tected  in  the  contralateral LN  draining the  foot pads  in- 
jected with either Flt3L-DC or with control DC  cultured 
in medium alone (Fig. 4). 
FIt3L Treatment Generates Large Numbers of DC in Multiple 
Tissues and Organs in Mice.  We next examined whether  the 
proportion of CDllc + or DEC205 + cells was increased in 
other  lymphoid  and  non-lymphoid  tissues.  The  relative 
number  of CDllc +  CDllb-  and  CD11c +  CDllb + cells 
was  significantly increased in  the  bone  marrow  (15-  and 
27-fold, respectively), liver (9- and 4-fold, respectively), PP 
(12-and  4-fold,  respectively),  and  thymus  (3-fold  for 
CDllc +  CDllb-  cells  only)  (Fig.  5  A).  Because  of the 
high level of CD 1 lc expression by activated lung and pen- 
toneal macrophages in normal and MSA-treated mice (data 
not shown), expression of DEC205  became a more defini- 
tive  DC  marker  in  these  tissues.  The  relative number  of 
DEC205 +  CDllb-  and DEC205 +  CD11b + cells was  ele- 
vated by 8- and  15-fold, respectively, in the lung and 29- 
and 2-fold, respectively, in the peritoneal cavity (Fig. 5  B). 
Furthermore,  a  2-fold increase in  cellularity was  observed 
in  these  tissues  (data  not  shown).  A  2-3-fold  increase  in 
nucleated cell number was observed in bone marrow, liver, 
PP,  lung lavage, and  peritoneal washings  of Flt3L-treated 
mice (data not shown). Both MSA and Flt3L-treated mice 
displayed a 2-3-fold reduction in thymic cellularity which 
could be attributed to stress-induced hypoplasia as a  result 
of daily manipulations of these mice. 
FIt3L but Not  GM-CSF,  GM-CSF Plus IL-4,  c-kitL,  or 
G-CSF Can  Generate Large Numbers of DC  When Adminis- 
tered In  Vivo.  In vitro,  DC  can  be  generated  from  bone 
marrow  progenitors  or  PBMC  using  GM-CSF  (but  not 
M-CSF  or  G-CSF)  (1,  17).  Furthermore,  several studies 
have shown that IL-4, TNF-ot and c-kitL can enhance the 
GM-CSF-dependent in vitro generation of DC  (8-17). To 
determine  the importance  of GM-CSF upon DC  genera- 
tlon in vivo, we compared the capacities of Flt3L or GM- 
CSF  (as  well as  a  non-DC  generating  cytokine,  G-CSF) 
upon  the  generation  of  DC  in  the  spleen.  Class  II  + 
CDllc +  cells were rare in the spleens of mice treated for 
11  consecutive days with either MSA alone, or with GM- 
CSF  or  G-CSF  (Fig.  6  A).  However,  treatment  of mice 
with Flt3L alone or Flt3L plus GM-CSF or G-CSF signifi- 
cantly increased the relative numbers  of class II  +  CD11c + 
cells in the spleen (Fig. 6 A). Although all the single growth 
factor treatments or Flt3L-containing growth factor combi- 
nations  resulted  in  an  increase  in  total  spleen  cellularity 
over 11  d, only mice treated with Flt3L or Fh3L-contain- 
ing combinations showed a 20- to 30-fold increase in class 
II + CD11c + spleen cells (Fig. 6  B). Interestingly, the addi- 
tion  of either GM-CSF or G-CSF to  Flt3L treatment  in- 
creased the total number  of class II  +  CDllc +  cells only a 
further 1.2- and 1.3-fold, respectively, indicating that for in 
Figure  5.  Detection  of DC  m multiple tissues and organs in Fh3L- 
treated  mice  but  not  MSA-treated  controls.  (A)  The  &stnbution  of 
CD1 lc and CD 1  lb on cells fi'om bone marrow, hver, PP, and thymus m 
MSA- and  Flt3L-treated nuce.  (B)  The  dlsmbunon  of DEC205 and 
CDllb on cells from lung and pentoneal  cavl  W m MSA- and Flt3L- 
treated mace. 
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Figure  6.  Detection of class II + CDllc + cells in growth factor-treated 
mace.  (A)  The  dlsmbutlon of class II  MHC  and  CD11c  in spleen cells 
from mace treated for 11 d with MSA alone, or with either Fh3L, G-CSF, 
GM-CSF,  or Flt3L plus G-CSF  or Flt3L plus GM-CSF.  (B)  Increases in 
total spleen  ceilulanty and  total numbers  of class II  +  CDllc + DC  over 
ume  in  growth  factor-treated  rmce  Groups  as  descnbed  above:  MSA 
alone (open  drcles),  G-CSF  (closed circles), GM-CSF  (open  triangles),  Flt3L 
(closed  triangles),  Fh3L  plus  G-CSF  (open  squares),  Flt3L  plus  GM-CSF 
(closed squares).  Growth factor treatment ceased at day 11 and spleens from 
the  various  groups  were  also  analyzed at  day  17.  Values  represent  the 
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and CD 1 lc m  spleen cells from mace treated for 11 d with MSA alone, or 
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vivo administration  Flt3L  (but not GM-CSF  or G-CSF)  is 
the  principle  growth  factor in  the  generation  of class  II  + 
CDllc + cells. In addition,  cessation of growth factor treat- 
ment at day 11  resulted in a reduction  in the total number 
of class  II  +  CD11c +  cells  by  day  17,  indicating  that  the 
generation of these cells was transient  (Fig.  6/3).  Compari- 
son of additional  growth factors in vivo such as c-kit-L (10 
Ixg/mouse/d)  or  GM-CSF  plus  IL-4  (10  txg  of  each/ 
mouse/d)  on the  development of class II  +  CDllc ÷ spleen 
cells is presented in Fig. 6  C. Although GM-CSF plus IL-4 
are  potent  in  vitro  stimulators  of DC  development  from 
bone  marrow  progenitors,  this  cytokine  combination  re- 
sulted in  only a  3-fold increase  in  the  relative  numbers  of 
class  II  +  CDllc +  spleen  cells  (Fig.  6  C).  Interestingly, 
GM-CSF plus IL-4-treatment of mice did increase the total 
spleen  cellularity  by 2-3-fold  (comparable  to  that  seen  in 
Flt3L-treated  mice)  suggesting  that  cells  of other  lineages 
were preferentially expanded in these mice (data not shown). 
Furthermore,  although  administration  of c-kitL resulted in 
a  5-fold  increase  in  CFU-GM  in  the  spleen  (data  not 
shown)  and  a  1.5-fold  increase  in  total  spleen  cellularity 
(data  not  shown),  there  was  no  significant  increase  in  the 
relative  numbers  of class  II  +  CD11c +  cells  in  the  spleen 
(Fig. 6  C). These results indicate that Flt3L is the most po- 
tent  growth  factor for the  generation  of large  numbers  of 
DC in vivo. 
Discussion 
Our data indicate that m  vivo administration of Flt3L re- 
sults in a dramatic numerical increase of DC in multiple tis- 
sues in  mice.  These  DC  are  as  efficient  at stimulating  the 
proliferation  of Ag-specific T  cells in vitro  or at inducing 
an Ag-specific T  cell response in vivo as the  rare DC  iso- 
lated from the spleens of untreated mice. Elevated numbers 
of DC  are detected in both lymphoid- and non-lymphoid 
tissue  in  Flt3L-treated  mice,  including  the  bone  marrow, 
GALT, liver, lymph nodes,  lung, peripheral blood,  perito- 
neal cavity, spleen, and thymus. Of particular interest is the 
elevated numbers  of DC  in  the  GALT, lung,  and  periph- 
eral blood which  are sites amenable  to vaccine delivery in 
clinical immunotherapy regimens. 
At least three phenotypically distinct DC subpopulations 
have been identified on the basis of CDllb  and CDllc  ex- 
pression  (populations  C,  D,  and E)  and these appear to be 
functionally similar in the Ag-mediated T  cell proliferation 
assays. Populations D  and E, which are either dull or nega- 
tive for CD11b  expression,  can be further  separated using 
CDSot expression  (a total of five DC subpopulations).  This 
surface phenotype  (CD1 lcbng  ht CD1 lb dun CD8o~ +) is simi- 
lar  to  that  of the  putative  lymphoid-derived  DC  popula- 
uons  (5,  18). Although  the generation  of these DC from a 
lymphoid  precursor  has  only  been  estabhshed  for thymic 
DC,  a  similar  CD8ot +  population  is found  in  spleen  and 
LN (5, 31). A  subclass of DC have recently been identified 
that co-express CD8o~ and high levels of FasL and kill acti- 
vated  Fas  expressing  CD4 +  T  cells  in  vitro  (32).  FasL- 
expressing  DC  may be  involved  in  the  regulation,  rather than stimulation,  of primary peripheral T  cell responses. It 
is  notable  that  although  cells  within  population  E  were 
highly efficient APC, they were consistently less efficient at 
stimulating the proliferation ofAg-specific T  cells than cells 
within populations C, D, or control DC. Interestingly, the 
highest proportion of CD80~ + DC are found within popu- 
lation E. The less efficient APC function by population E 
may be due to deletion of activated CD4 ÷ T  cells by FasL 
expression on the CD8ot + DC  (32).  We are currently ex- 
amining  the  proportion  of  FasL-expressing  cells  within 
each DC subpopulation identified in Flt3L-treated mice. 
Population  C  has  not  been  previously  described.  The 
high  CDllb  expression by population  C  suggests  a  rela- 
tionship to the myeloid lineage and it may represent an im- 
mature stage in  development of the myeloid-derived DC 
population (11,  15,  16, reviewed in reference 17).  It is also 
of note  that  mature  splenic  monocytes  and  macrophages 
are not clearly discernible in these mice. It is possible that 
the in vivo effects of Flt3L on myelopoiesis may result in 
the  terminal  differentiation  of developing monocytes and 
macrophages into DC or DC-like cells analogous to human 
monocytes treated with  GM-CSF and IL-4 (13,  14).  Re- 
cently, phenotypic, histological, and functional studies sug- 
gest that the cells within population C  are myelold-derived 
DC (Pulendran B., J. Smith, M. Teepe, E. Roux, C. Mal- 
iszewski, and E Maraskovsky, manuscript in preparation). 
Several studies  have  shown  that  GM-CSF  is  necessary 
for the  in vitro generation  of DC  from bone marrow or 
cord blood progenitors, or from PBMC (reviewed in refer- 
ence 17) and that this can be further enhanced by the addi- 
tion  of IL-4 or c-kitL  (13-17).  However,  although  GM- 
CSF  appears  to  be  necessary  in  vitro,  overexpresslon  of 
GM-CSF  in  GM-CSF  transgenic  mice  does  not  increase 
the  number  of DC  in  lymphoid  tissue,  suggesting  that 
other  growth  factors are  important  for DC  generation  m 
vivo  (20).  Interestingly,  GM-CSF  does  not  appear to  be 
necessary  for  DC  generation  from  lymphoid-committed 
precursors (19; Saunders, D., K. Lucas, J. Ismaili, L. Wu, E. 
Maraskovsky, D.  Dunn,  and  K.  Shortman,  manuscript m 
preparation). We report here that neither GM-CSF and IL-4 
nor c-kitL are as potent at stimulating the development of 
functionally mature DC in vivo as Flt3L. Furthermore, the 
multiple  subpopulations  of DC  identified  here  and  their 
apparent  relationship  to  either  the  lymphoid  or  myeloid 
developmental  pathways  suggests  that,  unlike  GM-CSF, 
Flt3L  enhances  the  development  of both  lymphoid-  and 
myeloid-derived DC populations. 
It is  unlikely  that  Flt3L  treatment simply results in  the 
mobilization  of existing mature DC  from other sites  into 
the lymphoid tissue.  First,  Flt3 receptor is not detected on 
mature DC as assessed by flow cytometry and mature DC 
do not proliferate when cultured in  Flt3L alone  (data not 
shown).  Second,  elevated numbers  of DC  have been de- 
tected in multiple organs and tissues  in Flt3L-treated mice, 
indicating  that  there  is  a  generalized  expansion  of DC 
throughout these mice. Finally, Brasel et al.  have recently 
shown that in vivo administration of Flt3L dramatically in- 
creases  the  numbers  of hematopoietlc  progenitors  in  the 
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BM,  peripheral  blood  and  spleen,  resulting  in  increased 
myelopoiesis and B  lymphopoiesis (27,  28).  These potent 
effects on hematopoiesis, as well as our observations on DC 
generation, suggest that in vivo administrafon of Flt3L fa- 
cilitates  the  terminal  development  of a  primitive,  Flt3L- 
sensitive,  rapidly  expanding  progenitor  population  into 
functionally  mature  DC.  This  hypothesis  is  further  sup- 
ported by studies showing that Flt3L can increase the abso- 
lute  numbers  of  mature  DC  generated  from  cultured 
CD34 ÷ human bone marrow progenitors (33, 34). In addi- 
tion, the early detection of DC in the secondary lymphoid 
organs  of mice  after Flt3L  treatment  may indicate  that  a 
more  mature  precursor  population  (such  as  a  CFU-DC) 
(16) is also induced to differentiate into DC when exposed 
to Flt3L  (or Flt3L-inducible  signals)  in vivo. We are cur- 
rently  investigating  whether  such  committed  precursor 
cells are responsive to Flt3L in vitro. 
The  use  of DC  as cellular vectors for tumor immuno- 
therapy is a promising strategy (21,  reviewed in reference 
23).  However,  the  fact that only limited  numbers  of DC 
can be generated in vitro from bone marrow progenitors or 
PBMC, and that only the myeloid-derived type of DC ex- 
pand in  GM-CSF  containing  cultures  (11-17),  may limit 
the utility of this clinical regimen. By expanding the num- 
bers of functionally mature lymphoid and myeloid-derived 
DC in Flt3L-treated mice, we can not only assess whether 
these  mice have a  more robust  or sensitized immune  re- 
sponse to antigenic challenge, but also which DC lineage is 
most efficient at inducing  effective tumor-specific immu- 
nity. In this regard, results from preliminary studies indicate 
that Flt3L-treated mice respond more efficiently to a tumor 
challenge in vivo. This appears to be associated with the in- 
duction  of a  T  cell-mediated  anti-tumor  response which 
can mediate the rejection of even established tumors (Lynch, 
D.H., A. Andreasen, E. Maraskovsky, R.E. Miller, andJ.C.L. 
Schuh,  manuscript submitted for publication).  Similar re- 
suits have been obtained with Flt3L gene-transduced breast 
cancer  cells  that  mediate  the  rejection  of  subsequently 
transplanted,  untransduced  breast  cancer  cells  (35).  These 
findings suggest that increasing the numbers of antigen pre- 
senting cells in vivo can enhance the generation of Ag-spe- 
cific immunity. 
It is not clear,  however, that Flt3L-treatment will have 
the same effects with all antigens. The development of Ag- 
specific immunity is a multifaceted phenomenon.  The na- 
ture  of the Ag,  the  route  of administration  and the  types 
and functional characteristics of the DC found at that site 
could all affect the magnitude and qualitative nature of the 
immune response generated. Therefore, a significant effort 
to  identify the  most efficient and appropriate methods  to 
elicit Ag-specific immunity with various types of Ag will 
be required to assess the feasibility of using Flt3L-induced 
DC in various forms of cellular immunotherapy. With this 
in mind, we are currently examining the capacity of Flt3L- 
treated mice to more efficiently elicit immunity to soluble 
Ag in the absence of chemical adjuvants. 
In  conclusion,  the  results in  the  present  study indicate 
that Flt3L is a potent inducer of DC when administered in vivo and may be an important growth factor for both the in 
vitro and in vivo generation of large numbers of function- 
ally mature DC. The feasibility of using DC as cellular ad- 
juvants must  now  be  tested  in  depth.  Furthermore,  the 
identification of  different  DC  subpopulations  may  ulti- 
mately lead to the identification of differing functions (e.g., 
stimulatory versus regulatory and control of T  cell cytokine 
production). The identification of functionally distinct DC 
subpopulations should in turn lead to  their more focused 
and effective use in immunotherapy. 
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